FGL2 and neoplasm: When FGL2 expression (positive vs negative) was entered as a covariable into a Cox multivariable analysis together with tumour mitotic count (⩽5 vs. >5 mitoses/50 HPFs), tumour size (as a continuous variable) and site (gastric vs nongastric) using RFS as the end point, FGL2 expression (HR = 0.56; 95% CI: 0.32–0.96; p =.036), low mitotic count (HR =0.25; 95% CI: 0.14–0.43; p < 0.001) and small tumour size (HR =0.93; 95% CI: 0.92–0.95; p < 0.001) were significantly associated with favourable RFS, whereas tumour site was not (HR = 0.90; 95% CI: 0.63–1.28; p =.555).